NPIL–Reckitt JV under strain - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

NPIL–Reckitt JV under strain

Mar 27, 2000

Reckitt Benckiser, the $ 3.1 bn parent of Reckitt & Colman (R & C) India is reviewing the company’s joint venture (JV) with Nicholas Piramal (NPIL). R & C India had transferred two of its over the counter pharmaceutical brands Dettol and Dispirin to the joint venture in which it held 20% while 40% each was held by its parent and NPIL respectively.

The transfer of the brands had hit the valuation of the listed company since the transfers were made without any consideration apart from giving R & C a 20% stake in the JV. Besides, it was also announced at the time of setting up of the venture that henceforth the pharmaceutical products of the parent would be introduced through the JV and not through R & C India.

The joint venture had a turnover of Rs 2.12 bn in the first nine months of FY 2000, a 9% growth over the previous year. This in fact is slightly over the overall formulations growth of 7% shown by the pharmaceutical industry. Companies such as Glaxo India that have a very high percentage of prescription brands have also grown by 9%. It is quite possible that had the brand remained with the listed company it would have grown equally if not more.

However, the impact of the reported review on the stocks of both R & C and NPIL is still not clear since an announcement on the future of the brands is still awaited. If the joint venture splits and the brands return to the R & C fold it would be a definite positive for the stock. (R & C ‘s parent had earlier requested the FIPB for setting up a 100% subsidiary which was rejected.)

NPIL has built a network of relationships with more than half a dozen alliances and joint ventures currently in operation. The importance of continuity in these relationships cannot be overstated. If for whatsoever reason relationships turn sour, it could damage NPIL’s value in the future.

Equitymaster requests your view! Post a comment on "NPIL–Reckitt JV under strain". Click here!


More Views on News

Sun Pharma vs Dr Reddy's: Which is Better? (Views On News)

Dec 16, 2021

In an extremely competitive market, two pharma companies are competing against each other to grab the top spot.

5 Stocks to Watch Out for Amid the Omicron Outbreak (Views On News)

Dec 3, 2021

As the new variant of Covid-19 emerges, keep an eye on these stocks.

This Stock Just Made a Historical Debut on the Exchanges (Views On News)

Nov 15, 2021

Shares of the company listed at premium of 253% from its IPO price, the highest ever.

3 Indian Pharma Companies that are Investing Big Time for the Future (Views On News)

Nov 9, 2021

In 2021, R&D of pharma companies roared to life in a never-before-seen way.

Demerger of Financial & Pharma Businesses puts Piramal Enterprises in Limelight (Views On News)

Oct 8, 2021

The company's shareholders will be issued 4 shares in the demerged entity for every 1 held in Piramal Enterprises.

More Views on News

Most Popular

India's Best Semiconductor Stocks Views On News (Views On News)

Jan 7, 2022

Modern wars are fought with semiconductors. India's best semiconductor stocks have big tailwinds from defence and manufacturing.

10 Indian Companies with the Fastest Growth in Dividend Payouts... (Views On News)

Jan 10, 2022

These companies have been consistently paying higher dividends for several years.

Tata Steel vs SAIL: Which Stock is Better? (Views On News)

Jan 13, 2022

With government initiatives set to boost the steel sector, find out who has a better chance of coming out on top.

Watch Out for these 4 Indian Companies Betting Big on EV Supply Chain (Views On News)

Jan 11, 2022

The upside in supply chain players could be huge but a delay in the transition to EVs, or any policy related hiccups could end the momentum.

Tech Mahindra's CTC Acquisition: Too Expensive? (Views On News)

Jan 18, 2022

Tech Mahindra's acquisition of European IT-company fails to excite investors.


Become A Smarter Investor
In Just 5 Minutes

Multibagger Stock Guide 2022
Get our special report Multibagger Stocks Guide (2022 Edition) Now!
We will never sell or rent your email id.
Please read our Terms


Mar 7, 2019 10:55 AM


  • Track your investment in RECKITT BENCKISER with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks